Similarly a 39‐week study with the levodopa/carbidopa/entacapone (LCE) combination showed a significant difference in total Unified Parkinson's Disease Rating Scale (UPDRS) scores in favor of the COMT inhibitor arm versus traditional levodopa/DDCI therapy [4]. Here, COMT is linked to Parkinson disease.